© DHL International GmbH. All rights reserved.
Deutsche Post DHL Group
Mandatory
** To receive your download, you must agree to "Opt-In" to receive future related emails from DHL Supply Chain. You may unsubscribe from our mailings at any time.

For complete information on how DHL protects your privacy, visit www.dhl.com.

Exel is a sister company of DHL.
Register to download the ‘Going Direct’ LSH supply chain strategy white paper:
1. Accenture, “Pharmaceutical Distribution: In a changing world, a decisive opportunity for margin improvement,” 2011, p. 2.
Thank you for your interest in our new paper, ‘Going Direct: Bold Strategy for Healthcare Supply Chains’. To download your free copy, please complete the brief form.
“Revenue from the sale of a pharmaceutical product typically has to be divided between a manufacturer, a distributor, a pharmacy and a jurisdiction (in the form of taxes and discounts). Self-evidently, to stay profitable… companies need to retain as much as possible of the sales prices.
1

New pressures facing LSH manufacturers include soaring costs, increasing financial risks, rapidly shrinking margins, greater buying power of new pharmacy conglomerates and the growing problem of counterfeiting.

As the white paper reveals, these pressures can be addressed by considering serving customers directly. The paper assesses current trends and shows how a direct-to-market (D2M) strategy achieves higher margins and a host of other benefits. It then examines when D2M is right for you, how to execute it and the key role a third party logistics (3PL) provider can play.

We hope you enjoy reading the white paper.
Share
GOING DIRECT: D2M AS A 
STRATEGY FOR CHANGING TIMES.

Accenture